P&F Products & Features

What P&F Products & Features does

P&F Products & Features GmbH is a privately held Austrian medical technology company founded in Vienna in 2004 by practicing cardiologist Dr. Katharina Kiss and engineer Dr. Siegfried Einhellig. The company designs, develops, manufactures, and commercializes minimally invasive transcatheter heart valve systems, with its flagship product being the TricValve Transcatheter Bicaval Valve System — a pair of self-expanding biological (bovine pericardium) valves implanted in the superior and inferior vena cava to treat severe tricuspid regurgitation in patients who are too high-risk for open-heart surgery. The platform is enabled by the company's proprietary Dry Pericardium tissue technology, which permits fully pre-mounted, off-the-shelf valve delivery without pre-implantation preparation, and is supported by a fully integrated global value chain spanning Nitinol stent production in Germany, tissue sourcing and final valve sewing in Brazil, and final assembly, packaging, and quality inspection in Germany.

The company's commercial model is direct enterprise field sales of Class III implantable hardware to interventional cardiologists, cardiac surgeons, and hospital systems, with a commercial footprint in approximately 70 countries built through wholly-owned subsidiaries in Austria, Germany, Spain, and Brazil, plus joint ventures with OrbusNeich (APAC) and Relisys Medical Devices (Indian subcontinent), and a U.S. subsidiary (P&F USA, Inc.) currently running FDA pivotal trials. Revenue is derived almost entirely from hardware sales of TricValve and the Vienna Aortic Valve SE. The company has more than 3,000 patients treated worldwide, holds the world's first CE Mark for a bicaval transcatheter valve system (initial May 2021 under MDD; February 2026 under EU MDR), FDA Breakthrough Device Designation, and is in the process of expanding its product portfolio to include transcatheter mitral, pulmonary, and combined aortic/ascending aorta (AortoSave) devices. The customer base spans hospital systems and cardiovascular centers globally, with anchor clinical relationships at flagship institutions such as Cleveland Clinic and Houston Methodist in the United States, and a broader network of adopters across Europe, Latin America, the Middle East, and Asia.

Name

P&F Products & Features

Legal name

P&F Products & Features GmbH

Website

https://productsandfeatures.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

P&F Products & Features is an Austrian medical technology company that develops and manufactures minimally invasive transcatheter heart valve systems, most notably the TricValve bicaval valve for severe tricuspid regurgitation, serving interventional cardiologists and hospital systems across approximately 70 countries.

Ownership category

akta.pro rank

Product category

Transcatheter Heart Valve Devices (Structural Heart)

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)

Keywords

• Structural heart devices
• Transcatheter heart valves
• Tricuspid regurgitation treatment
• Minimally invasive cardiology
• Bicaval valve implantation

Headquarters

HQ city

Wesseling

HQ country

Germany

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Others

Revenue model

1. TricValve® Transcatheter Bicaval Valve System Sales: P&F generates revenue through the sale of its TricValve system, a Class III active implantable medical device. The system is commercially available in approximately 70 countries globally. Revenue is derived from direct commercial sales to hospital systems and cardiology departments, supported by a network of sales representatives and distribution partnerships. The company also sells additional valve systems including the Vienna Aortic Valve SE.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

P&F Products & Features develops, manufactures, and commercializes minimally invasive transcatheter heart valve systems used by interventional cardiologists and cardiac surgeons to treat structural heart disease. Its flagship offering, the TricValve Transcatheter Bicaval Valve System, consists of two self-expanding bovine pericardium valves implanted percutaneously in the superior and inferior vena cava to treat severe tricuspid regurgitation. The company also offers the Vienna Aortic Valve SE transcatheter aortic valve system and pipeline products for mitral, pulmonary, and combined aortic/aorta (AortoSave) indications.

Differentiator

Problem solved

Functional benefit

Brands

• TricValve: TricValve Transcatheter Bicaval Valve System — a system of two self-expanding biological valves for treatment of hemodynamically relevant tricuspid insufficiency and caval reflux.
• Vienna Aortic Valve SE
• Munich Transcatheter Mitral Valve System
• Perspective Transcatheter Pulmonary Valve
• AortoSave (AortaSave)
• Dry Pericardium

Products and services

• TricValve Transcatheter Bicaval Valve System A system of two self-expanding biological (bovine pericardium) valves percutaneously implanted into the superior vena cava (SVC) and inferior vena cava (IVC) to treat severe tricuspid regurgitation and caval reflux without disturbing the native tricuspid valve. Available in SVC sizes 25mm and 29mm, and IVC sizes 31mm and 35mm. Indicated for patients at high risk or inoperable for open-heart surgery. Commercially available in approximately 70 countries with more than 3,000 patients treated.
• Vienna Aortic Valve SE Self-expandable TAVI system using bovine pericardium leaflets and skirt in sizes 23mm, 26mm, 29mm, and 31mm. Fully premounted design reduces preparation steps and procedure time. Supra-annular valve design with advanced sealing via consistent radial force of Nitinol frame. Indicated for treatment of severe aortic stenosis in patients at medium to high risk for open heart surgery.
• Munich Transcatheter Mitral Valve System Transcatheter mitral valve system for treatment of mitral regurgitation in high-risk surgical patients. Part of P&F's pipeline leveraging the proprietary Dry Pericardium technology platform.
• Perspective Transcatheter Pulmonary Valve Transcatheter pulmonary valve designed to treat pulmonary regurgitation in infants with congenital defects. Part of P&F's pipeline of minimally invasive structural heart devices.
• AortoSave Endo-Bentall System Next-generation transcatheter Endo-Bentall solution for combined aortic valve and ascending aorta replacement, addressing complex structural heart challenges.

Quantifiable outcome

• TricBicaval registry: 96.1% intraprocedural success rate across 204 patients at 26 European and 1 Brazilian hospital.
• +6 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• OrbusNeich Medical CompanycoreChannel Partner/ Reseller/ DistributorP&F entered into a Joint Venture with OrbusNeich for the APAC (Asia-Pacific) region. This partnership leverages OrbusNeich's established distribution network and market presence across Asia-Pacific countries to commercialize TricValve and other P&F cardiovascular products in those markets.
• Relisys Medical Devices Ltd.coreChannel Partner/ Reseller/ DistributorP&F entered into a Joint Venture with Relisys Medical Devices Ltd. for the Indian subcontinent and neighboring countries. This partnership extends P&F's distribution reach into one of the world's largest healthcare markets, with Relisys leveraging local market knowledge and regulatory expertise to commercialize P&F's transcatheter valve portfolio.
• Cardiovascular Research Foundation (CRF)minorStrategic or Co-development PartnerP&F participates in TCT (Transcatheter Cardiovascular Therapeutics), the foremost educational forum organized by the Cardiovascular Research Foundation (CRF). The company presents clinical data, participates in panel discussions, and showcases innovations at TCT, which serves as a key platform for driving adoption and building clinical evidence for the TricValve system.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Edwards Lifesciences: Global structural heart leader offering the PASCAL transcatheter system for tricuspid regurgitation and the Cardiovalve program for orthotopic transcatheter tricuspid replacement. Edwards is the most direct large-cap competitor in the TR space and sets the benchmark for transcatheter valve commercialization.
• Abbott: Major structural heart incumbent with TriClip, the first FDA-approved transcatheter edge-to-edge repair device for tricuspid regurgitation. Abbott's commercial scale, MitraClip platform synergies, and US sales infrastructure represent the primary competitive threat in the addressable TR market.
• Medtronic: Diversified structural heart player with transcatheter aortic (Evolut) and emerging mitral/tricuspid programs. Medtronic's global cardiac footprint and R&D resources position it as a broad incumbent across P&F's pipeline valve indications (aortic, mitral, pulmonary).
• Boston Scientific: Structural heart incumbent with the ACURATE neo2 TAVR platform and Watchman franchise, actively investing in transcatheter valve programs that overlap with P&F's Vienna Aortic Valve SE and broader pipeline.

Emerging players

• CroíValve: Dublin-based early-stage company developing a transcatheter device for tricuspid regurgitation. CroíValve is one of several emerging competitors targeting the same patient population P&F serves with TricValve.
• Innoventric: Israel-based medical device company developing the TriCares transcatheter tricuspid valve replacement system, directly competing in the structural heart TR space where P&F's TricValve is positioned.
• Venus MedTech: China-headquartered transcatheter heart valve company with a broad portfolio across aortic, mitral, pulmonary, and tricuspid indications, providing a comparable platform-play business model across multiple valve programs.
• 4C Medical Technologies: US-based developer of transcatheter mitral and tricuspid valve technologies (AltaValve system). 4C Medical competes in the same minimally invasive structural heart space with a particular focus on mitral and tricuspid regurgitation.
• JenaValve Technology: Developer of transcatheter aortic valve replacement systems (including alignment/leaflet technology). JenaValve directly overlaps with P&F's Vienna Aortic Valve SE in the TAVR segment of the structural heart market.
• Anteris Technologies: Australia/US-based developer of the DurAVR transcatheter aortic valve system using a single-piece biomimetic design. Anteris is a structural heart emerging player competing in adjacent valve indications to P&F's pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@ProductsFeaturesGmbH
• Facebookfacebook.com/productsandfeaturesgmbh
• LinkedInlinkedin.com/company/productsandfeatures
• Instagraminstagram.com/productsandfeaturesgmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about P&F Products & Features